Breaking News, Collaborations & Alliances

Cognate BioServices, Nucleus Biologics Form Cell & Gene Therapy Partnership

Will focus on clinical and commercial clients, especially as Cognate expands its business with allogeneic and autologous on-demand cell and gene therapies.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cognate BioServices, a global contract development and manufacturing organization (CDMO) in the cell and gene therapy industry, and Nucleus Biologics, have formed a partnership for custom and commercial medias and delivery systems for cell and gene therapy clients.   “We’re quite excited to be moving forward with Nucleus,” said J. Kelly Ganjei, chief executive officer, Cognate. “I am particularly pleased with this collaboration that has come to us from the front lines of ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters